TT-10 (PORT-6) and TT-4 (PORT-7) as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors

Recruiting

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(3 sites)

United States

USC Norris Comprehensive Cancer Center, Los Angeles, California

Norton Cancer Institute, Louisville, Kentucky

The University of Texas MD Anderson Cancer Center, Houston, Texas